Lupin launches Clobetasol Propionate ointment in US
New Delhi: Drug firm Lupin has launched generic Clobetasol Propionate ointment used for the treatment of inflammation and itching caused by a number of skin conditions in the US market.
The company has launched Clobetasol Propionate ointment USP in the strength of 0.05 per cent. It had earlier received approval for the product from theUnited States Food and Drug Administration (USFDA), Lupin said in a statement.
The company's product is the generic version of Fougera Pharmaceuticals Inc's Temovate ointment in the same strength, it added.
As per the IQVIA MAT June 2018 data, Clobetasol Propionate Ointment USP 0.05 per cent had annual sales of around USD 93.4 million in the US, it said.
"It is a super-high potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses," Lupin added.
Read Also: Lupin launches generic Potassium Chloride Oral Solution
The company has launched Clobetasol Propionate ointment USP in the strength of 0.05 per cent. It had earlier received approval for the product from theUnited States Food and Drug Administration (USFDA), Lupin said in a statement.
The company's product is the generic version of Fougera Pharmaceuticals Inc's Temovate ointment in the same strength, it added.
As per the IQVIA MAT June 2018 data, Clobetasol Propionate Ointment USP 0.05 per cent had annual sales of around USD 93.4 million in the US, it said.
"It is a super-high potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses," Lupin added.
Read Also: Lupin launches generic Potassium Chloride Oral Solution
Clobetasol PropionatecorticosteroidFougera PharmainflammationLupinTemovate OintmentUnited States Food and Drug Administration
Source : SelfMedical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Next Story
NO DATA FOUND
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd